Atherosclerosis
Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention
Mendelian randomization in 35,378 peopleMechanisms
Papers on apoC3
30 papers8 new in 30 days
Friday, March 29
Wednesday, April 19
Neurobiology of Aging
Plasma apolipoproteins and physical and cognitive health in very old individuals
Cohort study of 1,067 peopleBiomarkers